Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Semler Scientific Inc (SMLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/30/2025: SMLR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -7.4% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 505.93M USD | Price to earnings Ratio - | 1Y Target Price 71 |
Price to earnings Ratio - | 1Y Target Price 71 | ||
Volume (30-day avg) - | Beta 1.43 | 52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 |
52 Weeks Range 21.77 - 81.56 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.39 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.69% | Operating Margin (TTM) -15.29% |
Management Effectiveness
Return on Assets (TTM) 4.18% | Return on Equity (TTM) -24.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 592336349 | Price to Sales(TTM) 10.28 |
Enterprise Value 592336349 | Price to Sales(TTM) 10.28 | ||
Enterprise Value to Revenue 12.03 | Enterprise Value to EBITDA 7 | Shares Outstanding 13141100 | Shares Floating 10076783 |
Shares Outstanding 13141100 | Shares Floating 10076783 | ||
Percent Insiders 12.03 | Percent Institutions 50.34 |
Upturn AI SWOT
Semler Scientific Inc
Company Overview
History and Background
Semler Scientific, Inc. was founded in 2007. The company focuses on developing, manufacturing, and marketing products and services that assist healthcare providers in evaluating and treating chronic diseases. It has evolved from initially focusing on peripheral arterial disease (PAD) to expanding its product offerings.
Core Business Areas
- PAD Detection: The primary focus is the QuantaFlo system, which helps healthcare providers assess blood flow in the extremities to diagnose Peripheral Arterial Disease (PAD).
- Operational Intelligence: The company provides operational intelligence to medical providers to manage medical risk.
Leadership and Structure
The leadership team consists of Wayne T. Pan, President & Chief Executive Officer. The organizational structure is typical of a small, publicly traded company with departments for sales, marketing, R&D, and operations.
Top Products and Market Share
Key Offerings
- QuantaFlo System: QuantaFlo is Semler's primary product, used for the non-invasive diagnosis of PAD. Market share data is not readily available; however, the company focuses on the vascular assessment market. Competitors include companies offering Ankle-Brachial Index (ABI) testing and other vascular diagnostic tools.
Market Dynamics
Industry Overview
The industry is focused on diagnostics for cardiovascular and peripheral vascular diseases. It's driven by an aging population, increasing prevalence of diabetes and obesity, and technological advancements in non-invasive diagnostic methods.
Positioning
Semler Scientific is positioned as a provider of innovative, non-invasive diagnostic tools for PAD. Its competitive advantage lies in its QuantaFlo technology, which is designed to be more efficient and cost-effective than traditional methods.
Total Addressable Market (TAM)
The TAM for PAD diagnostics is estimated to be in the billions of dollars globally. Semler Scientific is positioned to capture a portion of this market by offering a cost-effective and efficient solution for PAD diagnosis.
Upturn SWOT Analysis
Strengths
- Proprietary QuantaFlo technology
- Focus on a specific niche market (PAD diagnostics)
- Strong financial performance (high profitability and revenue growth)
- Recurring revenue model (through disposables)
Weaknesses
- High customer concentration (reliance on a few large customers)
- Limited product diversification
- Small size relative to larger competitors
- Dependence on successful marketing and sales efforts
Opportunities
- Expanding into new geographic markets
- Developing new applications for QuantaFlo technology
- Acquiring complementary technologies or businesses
- Increasing awareness of PAD and the benefits of early diagnosis
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- MXL
- BIVV
Competitive Landscape
Semler Scientific's advantage lies in its QuantaFlo technology and focus on PAD diagnostics. Disadvantages include its smaller size and limited product diversification compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Semler Scientific has experienced strong revenue growth in recent years, driven by increasing adoption of its QuantaFlo system.
Future Projections: Future growth is expected to be driven by expanding into new markets, increasing awareness of PAD, and developing new applications for QuantaFlo technology.
Recent Initiatives: Recent strategic initiatives undertaken by Semler Scientific Inc.
Summary
Semler Scientific is a company focused on PAD diagnostics with promising technology. It benefits from strong revenue growth and high profitability. However, reliance on few customers and limited product range present risks. Expansion and diversification are keys to future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Semler Scientific Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2014-02-21 | CEO, President & Director Dr. Douglas Murphy-Chutorian M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 79 | Website https://www.semlerscientific.com |
Full time employees 79 | Website https://www.semlerscientific.com | ||
Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.